Longeveron (LGVN) vs Moleculin Biotech (MBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Moleculin Biotech is the larger company by market cap ($9.0 million vs $7.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGVN | MBRX |
|---|---|---|
| Share price | $2.48 | $0.442 |
| Market cap | $7.91M | $9.01M |
| 1-day change | +4.64% | +4.25% |
| P/E ratio (TTM) | — | 0.05 |
| EPS (TTM) | $-10.28 | $9.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.30 | $15.75 |
| 52-week low | $2.30 | $0.161 |
| Distance from 52-week high | -79.84% | -97.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2369.76% | +2614.93% |
| Average volume | 93.67K | 1.29M |
| Shares outstanding | 3.04M | 20.39M |
| Employees | 38 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Moleculin Biotech
MBRX stock →Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
LGVN vs MBRX FAQ
Which is bigger, Longeveron or Moleculin Biotech?
Moleculin Biotech (MBRX) is larger, with a market capitalization of $9.01M compared with $7.91M for Longeveron (LGVN).
Are Longeveron and Moleculin Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.